Aclarion, Inc. ACON 深 沪
已收盘 12-19 16:00:00 美东时间
6.20
-0.140
-2.21%
华盛通- 最 高6.35
- 今 开6.30
- 成交量 18.48万股
- 最 低 5.91
- 昨 收 6.34
- 总市值 361.09万
- 52周最高 3499.5105
- 市盈率 静 --
- 换手率 31.73%
- 52周最低 5.55
- 委 比 36.00%
- 总股本 58.24万
- 历史最高 586116.00
- 量 比 1.78
- 振 幅 6.94%
- 历史最低 5.91
- 每 手 1
- 风险率 338.36%
个股概要
财务分析
公司资料
相关新闻
分红派息
- 分时图
- 日k
- 周k
- 月k
相关新闻
更多Aclarion Announces Publication Of Featured Article Tech Update In Upcoming Special Pain Issue Of The International Journal Of Spine Surgery
Featured article strengthens growing body of clinical evidence for Nociscan by highlighting a successful case study Special Pain issue features breakthrough innovations shaping the future of spine careIJSS publishes
12-04 21:05
美股大行评级 | 最高352美元！14家机构连夜上调英伟达目标价；劳氏、塔吉特、Wix.com等遭多家机构下调目标价
今日重点评级关注：Ascendiant Capital：维持Aclarion"买入"评级，目标价从22美元升至23美元；HC Wainwright & Co.：维持Cullinan Therapeutics"买入"评级，目标价从24美元升至26美元
11-21 15:50
Ascendiant Capital Maintains Buy on Aclarion, Raises Price Target to $23
Ascendiant Capital analyst Lucas Ward maintains Aclarion (NASDAQ:ACON) with a Buy and raises the price target from $22 to $23.
11-20 18:41
Aclarion Q3 EPS $(2.93) Misses $(2.62) Estimate, Sales $18.942K Miss $40.000K Estimate
Aclarion (NASDAQ:ACON) reported quarterly losses of $(2.93) per share which missed the analyst consensus estimate of $(2.62) by 11.83 percent. This is a 99.8 percent increase over losses of $(1.50 thousand) per share
11-12 21:52
Beyond Silicon Valley To Scotch: AI Funding Surges
Explore AI funding trends beyond Silicon Valley. Discover investments spanning biotech & enterprise software, to alcohol & insurance.
10-22 22:34
港股早知道 | 紫金黄金国际Q3净利润3.85亿美元；中国人寿预计今年前三季度净利同比增长50%-70%
紫金黄金国际Q3净利润3.85亿美元；中国人寿预计今年前三季度净利同比增长50%-70%；赣锋锂业拟以约6.64亿元收购深圳易储44.2361%股权>>
10-20 07:58
洲际船务附属拟1710万美元出售一艘船舶
洲际船务（02409）发布公告，于2025年10月17日，卖方Seacon Manila Ltd（本公司的间接全资附属公司）、买方BULK EXPORTS...
10-20 07:53
洲际船务附属拟租赁三艘散货船
洲际船务（02409）发布公告，于2025年10月16日（联交所交易时段后），（1）各租船人（为本公司三间间接全资附属公司，SEACON ATLANTA ...
10-17 08:28
Aclarion Highlights Accelerating Growth, $13.3M Cash Balance, And AI-Driven Biomarker Validation Progress
Debt-free balance sheet with $13.3 million in cash as of today ($15.11 per share fully diluted) providing strategic flexibility for continued commercial growthNociscan scan volumes increase +89% year-over-year with third
10-14 18:11
Aclarion Provides Corporate Update Highlighting Market Expansion as CLARITY Trial Advances Toward Key Data Catalyst
Aclarion, Inc. reported strong financials, market adoption, and clinical trial progress in its Q3 2025 update. The company has a debt-free balance sheet with $13.3 million in cash, supporting commercial growth. Nociscan scan volumes increased 89% year-over-year, marking three consecutive quarters of record utilization across U.S., U.K., and E.U. markets. The CLARITY pivotal trial is advancing on schedule with early 3-month readouts expected in Q2...
10-14 10:09
